Cargando…

Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study

BACKGROUND: Accumulation of epicardial fat (EF) is associated with increased cardio-metabolic risks and coronary events, independently of traditional cardiovascular risk factors. Therefore, the reduction of EF volume (EFV) may be associated with reduced cardio-metabolic risks and future cardiovascul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouchi, Ryotaro, Terashima, Masahiro, Sasahara, Yuriko, Asakawa, Masahiro, Fukuda, Tatsuya, Takeuchi, Takato, Nakano, Yujiro, Murakami, Masanori, Minami, Isao, Izumiyama, Hajime, Hashimoto, Koshi, Yoshimoto, Takanobu, Ogawa, Yoshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335851/ https://www.ncbi.nlm.nih.gov/pubmed/28253918 http://dx.doi.org/10.1186/s12933-017-0516-8

Ejemplares similares

Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study
por: Fukuda, Tatsuya, et al.
Publicado: (2017)

Is visceral adiposity a modifier for the impact of blood pressure on arterial stiffness and albuminuria in patients with type 2 diabetes?
por: Bouchi, Ryotaro, et al.
Publicado: (2016)

Clinical relevance of dual-energy X-ray absorptiometry (DXA) as a simultaneous evaluation of fatty liver disease and atherosclerosis in patients with type 2 diabetes
por: Bouchi, Ryotaro, et al.
Publicado: (2016)

Indirect measure of visceral adiposity ‘A Body Shape Index’ (ABSI) is associated with arterial stiffness in patients with type 2 diabetes
por: Bouchi, Ryotaro, et al.
Publicado: (2016)

Ratio of visceral‐to‐subcutaneous fat area predicts cardiovascular events in patients with type 2 diabetes
por: Fukuda, Tatsuya, et al.
Publicado: (2017)

Gender difference in the impact of gynoid and android fat masses on the progression of hepatic steatosis in Japanese patients with type 2 diabetes
por: Bouchi, Ryotaro, et al.
Publicado: (2017)

Insulin Treatment Attenuates Decline of Muscle Mass in Japanese Patients with Type 2 Diabetes
por: Bouchi, Ryotaro, et al.
Publicado: (2017)

Association of diabetic retinopathy with both sarcopenia and muscle quality in patients with type 2 diabetes: a cross-sectional study
por: Fukuda, Tatsuya, et al.
Publicado: (2017)

Retrograde pyelonephritis and lumbar spondylitis as a result of Salmonella typhi in a type 2 diabetes patient with neurogenic bladder
por: Fukuda, Tatsuya, et al.
Publicado: (2015)

High visceral fat with low subcutaneous fat accumulation as a determinant of atherosclerosis in patients with type 2 diabetes
por: Bouchi, Ryotaro, et al.
Publicado: (2015)

Suppression of Extrapancreatic Glucagon by Octreotide May Reduce the Fasting and Postprandial Glucose Levels in a Diabetic Patient after Total Pancreatectomy
por: Okuma, Hideyuki, et al.
Publicado: (2017)

Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy
por: Nakano, Yujiro, et al.
Publicado: (2018)

Impact of increased visceral adiposity with normal weight on the progression of arterial stiffness in Japanese patients with type 2 diabetes
por: Bouchi, Ryotaro, et al.
Publicado: (2015)

Sarcopenia is associated with incident albuminuria in patients with type 2 diabetes: A retrospective observational study
por: Bouchi, Ryotaro, et al.
Publicado: (2017)

Increased visceral adiposity with normal weight is associated with the prevalence of non‐alcoholic fatty liver disease in Japanese patients with type 2 diabetes
por: Bouchi, Ryotaro, et al.
Publicado: (2015)

Sarcopenic obesity assessed using dual energy X-ray absorptiometry (DXA) can predict cardiovascular disease in patients with type 2 diabetes: a retrospective observational study
por: Fukuda, Tatsuya, et al.
Publicado: (2018)

Repeated Hypoglycemic Episodes with Postprandial Hyperinsulinemia after the Recovery from Acute Weight Loss Revealed by Continuous Glucose Monitoring and the Oral Glucose Tolerance Test
por: Masuda, Seizaburo, et al.
Publicado: (2017)

A Case of Refractory Hypothyroidism due to Poor Compliance Treated with the Weekly Intravenous and Oral Levothyroxine Administration
por: Nakano, Yujiro, et al.
Publicado: (2019)

Effects of luseogliflozin treatment on hyperglycemia-induced muscle atrophy in rats
por: Xie, Keyu, et al.
Publicado: (2023)

Sodium–glucose cotransporter 2 inhibitor‐induced changes in body composition and simultaneous changes in metabolic profile: 52‐week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
por: Sasaki, Takashi, et al.
Publicado: (2018)

Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus
por: Ejiri, Kentaro, et al.
Publicado: (2020)

Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)
por: Sugawara, Masahiro, et al.
Publicado: (2023)

Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction
por: Nakashima, Mitsutaka, et al.
Publicado: (2021)

Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study
por: Kario, Kazuomi, et al.
Publicado: (2020)

Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice
por: Bamba, Ryo, et al.
Publicado: (2021)

Concomitant use and interaction of a subcutaneous implantable defibrillator and epicardial pacemaker
por: Kajiyama, Takatsugu, et al.
Publicado: (2021)

Evaluation of potential activity of luseogliflozin on vascular proliferation in the mesenteric lymph node with or without vascular tumors in Sprague-Dawley rats in a carcinogenicity study
por: Sasaki, Minoru, et al.
Publicado: (2016)

Luseogliflozin, a SGLT2 Inhibitor, Does Not Affect Glucose Uptake Kinetics in Renal Proximal Tubules of Live Mice
por: Zhang, Anqi, et al.
Publicado: (2021)

Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure
por: Ejiri, Kentaro, et al.
Publicado: (2022)

The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1
por: Okamura, Takuro, et al.
Publicado: (2019)

Acquired hemophilia A developing cerebral infarction 36 days after the frequent administration of bypass hemostatic agents
por: Saito, Makoto, et al.
Publicado: (2018)

Influence of Luseogliflozin on Vaginal Bacterial and Fungal Populations in Japanese Patients With Type 2 Diabetes
por: Kusunoki, Masataka, et al.
Publicado: (2021)

Beneficial effects of luseogliflozin on lipid profile and liver function in patients with type 2 diabetes mellitus (BLUE trial): a single-center, single-arm, open-label prospective study
por: Hajika, Yuriko, et al.
Publicado: (2023)

Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet
por: Lee, Gendai
Publicado: (2022)

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
por: Qiang, Shirong, et al.
Publicado: (2015)

Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function
por: Yamauchi, Yuki, et al.
Publicado: (2022)

Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study
por: Miyake, Teruki, et al.
Publicado: (2022)

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
por: Seino, Yutaka, et al.
Publicado: (2015)

Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects
por: Kumagai, Yuji, et al.
Publicado: (2015)

Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study
por: Samukawa, Yoshishige, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f3a4u0fbtv2e9c1utalblfddot